Methods of Stimulating Appetite Using Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs
Summary
The USPTO published patent application US20260098072A1 by inventor Russell Potterfield on April 9, 2026, covering methods of increasing body weight and stimulating appetite using non-naturally occurring melanocortin receptor antagonist analogs. The application, filed April 18, 2025, relates to pharmaceutical compositions administered via parenteral routes such as subcutaneous injection for subjects requiring appetite stimulation and weight gain.
What changed
The USPTO published patent application US20260098072A1 covering methods of increasing body weight and stimulating appetite using non-naturally occurring melanocortin receptor antagonist analogs. The patent claims pharmaceutical compositions and methods of administration via parenteral routes including subcutaneous injection.
For companies developing weight management or appetite-related therapeutics, this published application represents a potential barrier to market entry. Competitors should review the claimed scope for Freedom to Operate analysis and consider potential licensing or design-around strategies.
What to do next
- Monitor for patent grant
- Conduct Freedom to Operate analysis if developing related therapeutics
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS
Application US20260098072A1 Kind: A1 Apr 09, 2026
Inventors
Russell Potterfield
Abstract
Provided are methods of increasing body weight of and/or increasing food consumption in a metabolically unchallenged subject using non-naturally occurring melanocortin analogs. Also provided are methods of stimulating appetite in a subject via administration of non-naturally occurring melanocortin analogs. The non-naturally occurring melanocortin analog can be present in a pharmaceutical composition and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and/or fat mass of the subject.
CPC Classifications
C07K 14/665 A61P 3/00 A61K 38/00
Filing Date
2025-04-18
Application No.
19183258
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.